Ravagalimab
Product Specifications
UNSPSC Description
Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab can be used for research of Crohn's disease[1].
Target Antigen
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ravagalimab.html
Purity
99.31
Solubility
10 mM in DMSO
Smiles
[Ravagalimab]
References & Citations
[1]Argiriadi MA, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. |[2]Yu X, et al. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell. 2020 Jun 8;37(6):850-866.e7.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99821/Ravagalimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99821/Ravagalimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2050816-56-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
20035141 1x10<sup>6</sup> cells/1.0ml
FAM47A CRISPR Knock Out 293T Cell Line (Human)
Ask
View Details